EP 300
Alternative Names: EP300Latest Information Update: 28 Sep 2021
At a glance
- Originator Louisiana State University
- Developer Esperance Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Peptide drug conjugates
- Mechanism of Action Angiogenesis inhibitors; Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)
- 01 Feb 2020 EP 300 is available for licensing as of 01 Feb 2020. https://esperancepharma.com/strategic-alliances/